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Abstract
Background: Information is currently limited on the long-term follow up of HIV-1 infected women who are on
highly active antiretroviral therapy (HAART) that contains nevirapine and lamivudine and who were previously
exposed to antiretroviral drugs for the prevention of mother to child transmission (PMTCT) of HIV.
Methods: We studied the 36-month immunological response to HAART in HIV-1 infected women in Côte d’Ivoire.
The women were previously exposed to antiretroviral drug regimens for PMTCT, including single-dose nevirapine
and/or short-course zidovudine with or without lamivudine. All HAART regimens included a non-nucleoside reverse
transcriptase inhibitor.
Results: At 36 months: the median absolute increase in CD4+ T cell count was +359 cells/mm
3 (IQR: 210-466) in
200 women who had undergone 36-month follow-up visits; +359 cells/mm
3 (IQR: 222-491) in 88 women not
exposed to PMTCT antiretrovirals; and +363 cells/mm
3 (IQR: 200-464) in 112 women exposed to at least one
antiretroviral PMTCT regimen. Overall, 49 (19.8%) of the 247 women who initiated HAART met the immunological
failure criteria at least once during follow up. The overall probability of immunological failure was 0.08 (95% CI:
0.12-0.15) at 12 months, and 0.21 (95% CI: 0.16-0.27) at 36 months. No difference was observed according to the
presence or absence of resistance mutations to nevirapine or lamivudine in women tested at four weeks
postpartum. In addition, at 36 months, 23% of women were lost to follow up, dead or had stopped their
treatment.
Conclusions: A non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen, initiated a year or more
after PMTCT exposure and that includes nevirapine, remains a good option for at least the first 36 months of
treatment.
Background
Information is currently limited on the long-term fol-
low-up of HIV-1 infected women who are on highly
active antiretroviral therapy (HAART) containing nevir-
apine (NVP) and lamivudine (3TC) and who were pre-
viously exposed to antiretroviral (ARV) drugs for the
prevention of mother to child transmission (PMTCT) of
HIV [1-4].
A 12-month study showed a good immunological
response in women previously exposed to ARV drugs
for PMTCT [2]. However, in this study we found a
higher risk of virological failure in women who had
3TC-acquired resistance mutation four weeks postpar-
tum [2]. We now report the immunological response to
HAART at 36 months in women previously exposed to
short-course ARV prophylaxis and study factors asso-
ciated with immunological failure or with immunologi-
cal failure and death according to the history of
PMTCT exposure.
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A prospective cohort study was conducted in Abidjan,
Côte d’Ivoire, between August 2003 and June 2009
among all HIV-infected women who initiated HAART
in the MTCT-Plus initiative. The study population and
study design have previously been described [2].
Very briefly, our population consisted of: (1) women
never exposed to any treatment for PMTCT; (2) women
exposed to single-dose NVP (sdNVP) and zidovudine
(ZDV) for PMTCT; and (3) women exposed to short-
course zidovudine (scZDV) and 3TC for PMTCT. The
primary variable of interest was the presence of viral
resistance mutation to NVP or 3TC measured at Week
4 postpartum.
Two outcomes were considered after 36 months on
HAART: (1) immunological failure, defined as a 50% fall
from absolute CD4+ T cell count peak level [5]; and (2)
a combined criteria, defined as either immunological
f a i l u r eo rt h eo c c u r r e n c eo fd e a t hd u r i n gt h ef i r s t3 6
months of follow up. The virological analyses were done
retrospectively, and results were not available for clinical
use. Decisions to switch antiretroviral regimens were
thus made by local clinicians based on routinely col-
lected immunological and clinical data.
Other study variables measured at time of HAART
initiation were included in the analysis: age, WHO clini-
cal stage, body mass index, hemoglobinemia at HAART
initiation, and self-reported adherence (seven-day self-
report at six, 12, 18, 24, 30 and 36 months) [5]. Cox
regression was used to identify factors associated in uni-
variable analysis (p < 0.20) with immunological failure
or the combined criteria. We censored the follow up of
each patient at the date of last visit, or death, or date of
switch to a protease inhibitor (PI) to evaluate the
response to non-nucleoside reverse transcriptase inhibi-
tor (NNRTI)-based treatment.
Results
From August 2003 to September 2005, 247 women
initiated 3TC-containing HAART with either NVP or
efavirenz (EFV). At HAART initiation, their median age
was 28 years (interquartile range: 25-32) and their med-
ian CD4+ count was 188 cells/mm
3 (IQR: 126-264).
Overall, 28 women (11.3%) were classified at WHO clin-
ical Stage 1; 110 (44.5%) at Stage 2; 96 (38.9%) at Stage
3; and 13 (5.3%) at Stage 4. A total of 109 women
(44.1%) had never been exposed to a PMTCT ARV regi-
men during a previous pregnancy, and 138 (55.9%) had
previously received a PMTCT regimen: 50 had received
scZDV + sdNVP and two sdNVP only; 81 had received
scZDV+sc3TC+sdNVP and five scZDV+3TC only.
Among 73 of the 86 3TC-exposed women tested for
resistance mutations at Week 4 postpartum, 11 (15.1%)
had detectable 3TC resistance mutations. Among 111 of
the 133 sdNVP-exposed women tested at Week 4 post-
partum, 19 (17.1%) had detectable NVP resistance
mutations.
The first-line HAART regimen was ZDV+3TC+NVP
in 234 (95.1%) women, and stavudine (d4T)+3TC+NVP
in seven (2.9%) women; five women started HAART
with ZDV+3TC+EFV and one began with d4T+3TC
+EFV. The median time between exposure to sdNVP
and initiation of HAART was 21 months (IQR: 13-26).
During the 36 months of follow up, 30 women (12.1%)
were lost to follow up, 10 (4.0%) stopped treatment at
their own request, and 17 (6.9%) died. Furthermore, 19
out of 247 (7.7%) HIV-infected women switched to PI-
based HAART. The reasons for switching were immu-
nological failure in four patients and side effects related
to NVP or EFV in 15 cases. There was no association
between switching to PI and PMTCT-acquired resis-
tance to NVP (p = 0.43) or to 3TC (p = 0.93).
At 36 months, the median absolute increase in CD4+
count was +359 cells/mm
3 (IQR: 210-466) in 200
women who had undergone 36-month follow-up visits.
T h ei n c r e a s ew a s+ 3 5 9c e l l s / m m
3 (IQR: 222-491) in 88
w o m e nn o te x p o s e dt oP M T C TA R V ,a n d+ 3 6 3c e l l s /
mm
3 (IQR: 200-464) in 112 women exposed to at least
one ARV PMTCT regimen. The median absolute
increase in CD4 count was +366 cells/mm
3 (IQR: 174-
461) in the 18 women with NVP resistance at Week 4
postpartum, and > 230 cells/mm3 (IQR: 130-403) in the
eight women with 3TC resistance mutations detected at
Week 4 postpartum (Figures 1A and 1B). When analyses
of immunological response were restricted to the 184
women who did not switch to a PI during the follow up,
the median absolute increase in CD4+ count was 361
cells/mm
3 (IQR: 220-466) at 36 months.
Overall, 49 (19.8%), (95% CI 15.0-25.3%) of the 247
women who initiated HAART met the immunological
failure criteria at least once during follow up. Regarding
immunologic failure, no statistical difference was found
between the women unexposed to sdNVP, those
exposed to NVP without resistance mutations, and
those with NVP resistance mutations at Week 4 post-
partum (14.7% vs. 19.8% vs. 25.0%, respectively, p =
0.50). The same conclusion was drawn for 3TC expo-
sure (14.7% in women unexposed to 3TC vs. 14.8% in
women exposed without 3TC-resistance mutation vs.
18.2% in women exposed with 3TC-resistance muta-
tions, p = 0.71).
The overall probability of immunological failure was
0.08 (95% CI: 0.12-0.15) at 12 months, 0.14 (95% CI:
0.10-0.19) at 24 months and 0.21 (95% CI: 0.16-0.27) at
36 months. At 36 months, the probability of immunolo-
gical failure was 0.25 (95% CI: 0.18-0.28) in women who
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(95% CI: 0.14-0.31) in women who selected a NVP-
resistant virus.
For the second outcome (death or immunological fail-
ure), the probability at 36 months was 0.26 (95% CI:
0.20-0.31) in the overall population. It was 0.32 (95% CI:
0.16-0.58) in women who had NVP resistance mutations
at Week 4, and 0.30 (95% CI: 0.11-0.68) in women with
3TC resistance mutation at Week 4.
In multivariate analysis (n = 247), the only factor asso-
ciated with immunological failure was poor self-reported
adherence (adjusted Hazard Ratio, aHR, 2.61; 95% CI
1.43-4.74, p = 0.002), controlling for resistance muta-
tions and exposure to NVP or 3TC, CD4 count,
Figure 1 Immunological response in HIV-infected women. A. Immunological response in HIV-infected women exposed to nevirapine or
acquired PMTCT resistance to nevirapine. B. Immunological response in HIV-infected women exposed to lamivudine or acquired PMTCT
resistance to lamivudine. NVP = nevirapine. 3TC = lamivudine. N = number of patients with CD4 count available at baseline (M0). n = number of
patients with CD4 count available at month 36 (M36).
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at HAART initiation. Self-reported adherence was also
associated with the combined criteria (aHR 4.14; 95% CI
2.39-7.19, p < 0.001).
Discussion
During the 36 months of follow up, we did not find any
differences for immunological failure related to the pre-
sence or absence of NVP- or 3TC-resistance mutations
at Week 4 postpartum. Our findings are consistent with
those reported by others for shorter periods of follow
up [1-4,6], and support the recommendation to use
NNRTI-based regimens in women previously exposed to
NVP when the delay between the exposure to NVP and
H A A R Ti n i t i a t i o ni sl o n g e rt h a n1 2m o n t h s[ 6 ] .T h e
long delay between PMTCT exposure and HAART
initiation in our study likely resulted in the fading of
detectable resistance mutations acquired with PMTCT
ARV exposure [7,8].
We also reported that 7.7% of the women switched
from NNRTI-based to PI-based HAART during follow
up. Among the 19 women who switched to PI-based
HAART, only four switches were related to treatment
failure; the other 15 were done to manage NNRTI-
related drug toxicity. While 49 (19.8%) women met
immunologic criteria for failure at least once during fol-
low up, very few were changed to second-line therapy.
Similar findings have been reported in the Médecins
Sans Frontières multi-country cohort, with an incidence
of switch of 4.8 per 1000 person -years [9]. Reasons that
patients did not switch were not recorded, but we
hypothesize that this is a common practice in settings
with limited availability of ARV drugs, and where physi-
cians often choose to reinforce adherence and postpone
regimen changes in clinically stable patients.
Two limitations are noted. First, there is a lack of viral
load data, which is not routinely monitored and
recorded in our study area. Such data is important to
fully understand the dynamics and rate of treatment fail-
ure in our population. Switching treatments without
using viral load data for making these decisions is
indeed of utmost concern [10,11]. Second, the limited
sample size implies limited statistical power to detect
any immunologic difference between the groups of
interest variable studied. However, our results were con-
sistent with previous reports [3,4,6].
In addition, 23% of women were lost to follow up,
dead or had stopped treatment at 36 months, and were
no longer on treatment despite the establishment of a
well-funded programme with excellent resources [12].
However, very few data are available on long-term fol-
low up of ART treatment in low income-countries to
make any comparison between studies. In sub-Saharan
Africa, 38% of patients were lost to care and therefore
no longer on treatment after two years of follow up [13].
Conclusions
In conclusion, an NNRTI-based antiretroviral regimen,
which includes NVP, initiated at least one year after
PMTCT exposure remains a good option for at least the
first 36 months of treatment. Larger studies, preferably
with virological and genotypic test data, are needed to
confirm our findings and to better decide when to
switch HAART regimens.
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